Art. -Nr.: HY-N0412

Sesamoside

Kundenbewertung

Based on 1 Customer Validation

Sesamoside is an orally active anti-inflammatory, anti-hypoxic and analgesic agent. Sesamoside inhibits the phosphorylation of ERK and JNK, downregulates NLRP3 expression, restricts the nuclear localization of P65, regulates AKR1B1 expression, and reduces the expression of TRPV1 gene in the spinal cord. Sesamoside reduces the production of TNF-α, IL-6, IL-1β, iNOS and NO, restores cellular metabolism and organ function, and alleviates cold and mechanical hyperalgesia. Sesamoside can be used in research related to septic shock, high-altitude pulmonary edema and neuropathic pain.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 117479-87-5
Formel: C₁₇H₂₄O₁₂
Molecular Weight:420.37

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Sesamoside Chemical Structure

CAS. Nr.: 117479-87-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

Sesamoside (25-500 µM; 12 h) shows no cytotoxicity in mouse Raw264.7 cells even at concentrations up to 200 µM, with an IC₅₀ of 246.4 µM, and only induces significant apoptosis at the concentration of 500 µM^[1].
Sesamoside (25-200 µM; 6-24 h) dose-dependently and time-dependently inhibits the LPS (HY-D1056)-induced upregulation of TNF-α, IL-6, IL-1β and iNOS mRNA expression as well as NO production in mouse Raw264.7 cells^[1].
Sesamoside (200 µM; 6-24 h) inhibits LPS-induced activation of the NF-κB/MAPK pathway in mouse Raw264.7 cells by reducing the phosphorylation levels of ERK and JNK, and downregulating NLRP3 protein expression in a time-dependent manner^[1].
Sesamoside (200 µM; 6-24 h) inhibits LPS-induced nuclear localization of P65 in murine Raw264.7 cells in a time-dependent manner at the concentration of 200 µM^[1].
Sesamoside binds tightly to human aldose reductase (AR/AKR1B1) with a binding energy of -5.5 kcal/mol^[2].
Pretreatment of human bronchial epithelial BEAS-2B cells with sesamoside (200 μM; 6 h) significantly attenuates hypoxia-induced upregulation of AR, ERK, VEGF-α and TNF-α mRNA expression, elevates hypoxia-downregulated IL-10 mRNA expression, and reduces hypoxia-induced IL-6 secretion, but exerts no significant effect on HIF-1α mRNA expression^[2].
Pretreatment of human bronchial epithelial BEAS-2B cells with sesamoside (200 μM; 6 h) reduces hypoxia-induced IL-6 secretion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

mouse Raw264.7 macrophage cells
Concentration:

25, 50, 100, 200, 500 µM
Incubation Time:

12 h
Result:

Showed almost no cytotoxicity at concentrations up to 200 µM, with an IC₅₀ value of 246.4 µM.
Induced 31.61% apoptosis at 500 µM, while concentrations up to 200 µM caused negligible apoptosis.

Real Time qPCR^[1]

Cell Line:

mouse Raw264.7 macrophage cells
Concentration:

25, 50, 100, 200 µM (6 h incubation); 200 µM (6, 12, 24 h incubation)
Incubation Time:

6 h (25-200 µM); 6, 12, 24 h (200 µM)
Result:

Blocked LPS-induced increases in TNF-α, IL-6, IL-1β, and iNOS mRNA transcription at 25-200 µM for 6 h, with 200 µM showing the strongest effect.
Significantly inhibited mRNA transcription of all four targets and reduced NO production at 200 µM for 6, 12, or 24 h, with the inhibitory effect generally increasing with longer incubation times.

Western Blot Analysis^[1]

Cell Line:

mouse Raw264.7 macrophage cells
Concentration:

200 µM
Incubation Time:

6, 12, 24 h
Result:

Inhibited LPS-induced phosphorylation of ERK and JNK, and downregulated NLRP3 protein expression, with the inhibitory effect increasing in a time-dependent manner over 6-24 h.

Immunofluorescence^[1]

Cell Line:

mouse Raw264.7 macrophage cells
Concentration:

200 µM
Incubation Time:

6, 12, 24 h
Result:

Restricted LPS-induced nuclear translocation of P65 in a time-dependent manner, with the lowest nuclear P65 intensity observed after 24 h of treatment.

Real Time qPCR^[2]

Cell Line:

human bronchial epithelial BEAS-2B cells
Concentration:

200 μM (pre-treatment); 800 μM (CoCl₂, hypoxia induction)
Incubation Time:

6 h (pre-treatment); 6 h (hypoxia induction)
Result:

Significantly reduced the hypoxia-induced upregulation of AR, ERK, and VEGF-α mRNA expression compared to the hypoxia-only group.
Significantly reduced the hypoxia-induced upregulation of TNF-α mRNA expression compared to the hypoxia-only group.
Significantly increased the hypoxia-downregulated IL-10 mRNA expression compared to the hypoxia-only group.
Partially reduced the upregulation of IL-6 mRNA expression compared to the hypoxia-only group, but the effect was not statistically significant.
Significantly reduced the hypoxia-induced increase in IL-6 concentration in cell supernatant compared to the hypoxia-only group.
Partially reduced TNF-α secretion compared to the hypoxia-only group, but the effect was not statistically significant.
Had no significant impact on hypoxia-downregulated HIF-1α mRNA expression compared to the hypoxia-only group.

ELISA Assay^[2]

Cell Line:

human bronchial epithelial BEAS-2B cells
Concentration:

200 μM (pre-treatment); 800 μM (CoCl₂, hypoxia induction)
Incubation Time:

6 h (pre-treatment); 6 h (hypoxia induction)
Result:

Significantly reduced the hypoxia-induced increase in IL-6 concentration in cell supernatant compared to the hypoxia-only group.
Partially reduced TNF-α secretion compared to the hypoxia-only group, but the effect was not statistically significant.

In Vivo

Sesamoside (1-10 mg/kg; i.p.; single dose) dose-dependently reduces LPS-induced inflammatory responses and multi-organ damage in septic shock mice by inhibiting the NF-κB/MAPK signaling pathway^[1].
Sesamoside (5-7.5 mg/kg; i.p., p.o.; single dose) alleviates Paclitaxel (HY-B0015)-induced cold and mechanical peripheral neuropathy in mice, with 7.5 mg/kg doses (both intraperitoneal and oral) showing consistent efficacy, and oral 7.5 mg/kg sesamoside reducing spinal TRPV1 gene expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming mice (male, 8-10 weeks old, specific pathogen-free, intraperitoneal injection of 10 mg/kg LPS)^[1]
Dosage:

1 mg/kg; 5 mg/kg; 10 mg/kg
Administration:

i.p.; single dose
Result:

Significantly alleviated LPS-induced multi-organ damage to the heart, liver, spleen, lungs, and kidneys, reducing tissue congestion, edema, bleeding foci, and inflammatory cell infiltration in a dose-dependent manner.
Dose-dependently reduced mRNA transcription of pro-inflammatory cytokines TNF-α, IL-6, IL-1β, and iNOS in spleen tissue.
Inhibited LPS-induced phosphorylation of ERK and JNK, decreased protein expression of NLRP3 and P65 in spleen tissue.
Dose-dependently reduced nuclear localization of P65 in multiple organs.

Animal Model:

C57BL/6 (male, 6-week-old, peripheral neuropathy induced by paclitaxel)^[3]
Dosage:

5 mg/kg; 7.5 mg/kg
Administration:

i.p.; single dose; p.o.; single dose
Result:

Significantly reduced cold hypersensitivity (decreased response frequency in acetone drop tests) and increased mechanical sensitivity threshold (increased 50% threshold value in von Frey filament tests) at 7.5 mg/kg i.p. compared to paclitaxel + PBS controls.
Showed no significant effect on cold or mechanical hypersensitivity at 5 mg/kg i.p. compared to paclitaxel + PBS controls.
Significantly reduced cold hypersensitivity at 5 mg/kg and 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Significantly increased mechanical sensitivity threshold at 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Showed no significant effect on mechanical sensitivity threshold at 5 mg/kg p.o. compared to paclitaxel + PBS controls.
Significantly downregulated spinal TRPV1 gene expression at 7.5 mg/kg p.o. compared to paclitaxel + PBS controls.
Showed no significant effect on spinal TRPV1 gene expression at 5 mg/kg p.o. compared to paclitaxel + PBS controls.

Chemical Information

CAS. Nr. 117479-87-5
Appearance Solid
Molecular Weight 420.37
Formel C₁₇H₂₄O₁₂
Color White to off-white
SMILES

O=C(OC)C1=CO[C@@H](O[C@@]2([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@]3([H])[C@]1(O)[C@H](O)[C@H]4[C@]3(C)O4
Structure Classification
- Terpenoids
- Iridoids
Initial Source
- Plants
- Labiatae
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (237.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3789 mL

11.8943 mL

23.7886 mL

5 mM

0.4758 mL

2.3789 mL

4.7577 mL

10 mM

0.2379 mL

1.1894 mL

2.3789 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Song D, et al. The amelioration effect of sesamoside on inflammatory response in septic shock. BMC Immunol. 2025;26(1):15. Published 2025 Mar 6. [Content Brief]

[2]. Song D, et al. The Anti-Hypoxic Mechanism of Sesamoside Determined Using Network Pharmacology. Dose Response. 2024;22(3):15593258241282574. Published 2024 Sep 7. [Content Brief]

[3]. Park KT, et al. Phlomidis Radix Extract Alleviates Paclitaxel-Induced Neuropathic Pain by Modulating Spinal TRPV1 in Mice. Plants (Basel). 2023 Nov 10;12(22):3819. [Content Brief]

[4]. Fuji Y, et al. Chemical characterization and biological activity in young sesame leaves (Sesamum indicum L.) and changes in iridoid and polyphenol content at different growth stages. PLoS One. 2018;13(3):e0194449. Published 2018 Mar 27. [Content Brief]

[5]. Yu Y, et al. Hedyotis chrysotricha aqueous extract inhibits hepatitis B surface antigen and viral replication via hepatocyte nuclear factor 4α regulation. Phytomedicine. 2025 Jul 25;143:156726. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3789 mL	11.8943 mL	23.7886 mL	59.4714 mL
	5 mM	0.4758 mL	2.3789 mL	4.7577 mL	11.8943 mL
	10 mM	0.2379 mL	1.1894 mL	2.3789 mL	5.9471 mL
	15 mM	0.1586 mL	0.7930 mL	1.5859 mL	3.9648 mL
	20 mM	0.1189 mL	0.5947 mL	1.1894 mL	2.9736 mL
	25 mM	0.0952 mL	0.4758 mL	0.9515 mL	2.3789 mL
	30 mM	0.0793 mL	0.3965 mL	0.7930 mL	1.9824 mL
	40 mM	0.0595 mL	0.2974 mL	0.5947 mL	1.4868 mL
	50 mM	0.0476 mL	0.2379 mL	0.4758 mL	1.1894 mL
	60 mM	0.0396 mL	0.1982 mL	0.3965 mL	0.9912 mL
	80 mM	0.0297 mL	0.1487 mL	0.2974 mL	0.7434 mL
	100 mM	0.0238 mL	0.1189 mL	0.2379 mL	0.5947 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sesamoside

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Natural Product Library

Anti-Aging Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Parkinson's Disease Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Alle JNK Isoform-spezifische Produkte anzeigen

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Sesamoside Related Classifications

HY-N0412 Related Classifications